2-Methylthioadenosine diphosphate (2-MeSADP) is an agonist of purinergic P2Y receptors with EC50s of 5.13 and 0.89 nM for human recombinant P2Y1 and P2Y12 receptors, respectively.1 It also acts as an agonist at rat P2Y1 and P2Y12 and mouse P2Y13 receptors (EC50s = 0.58, 0.89, and 6.2 nM, respectively).1,2 It induces platelet aggregation and inhibits cyclic AMP accumulation in platelet-rich plasma stimulated by prostaglandin E1 more potently than ADP .3
1.Sak, K., and Webb, T.E.A retrospective of recombinant P2Y receptor subtypes and their pharmacologyArch. Biochem. Biophys.397(1)131-136(2002) 2.Zhang, F.L., Luo, L., Gustafson, E., et al.P2Y13: Identification and characterization of a novel Gαi-coupled ADP receptor from human and mouseJ. Pharmacol. Exp. Ther.301(2)705-713(2002) 3.Macfarlane, D.E., Srovastava, P.C., and Mills, D.C.2-Methylthioadenosine[β-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood plateletsJ. Clin. Invest.71(3)420-428(1983)